Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: A meta-analysis of randomized controlled trials

Hypertension Research

Volumn 36, Issue 4, 2013, Pages 368-373

  Takagi, Hisato ^a   Mizuno, Yusuke ^a   Yamamoto, Hirotaka ^a   Goto, Shin Nosuke ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

interleukin 6; meta analysis; telmisartan; tumor necrosis factor alpha

Indexed keywords

AMLODIPINE; ENALAPRIL; EPIRUBICIN; INTERLEUKIN 6; IRBESARTAN; LOSARTAN; OLMESARTAN; ORAL ANTIDIABETIC AGENT; PLACEBO; RAPAMYCIN; ROSIGLITAZONE; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CANCER CHEMOTHERAPY; COCHRANE LIBRARY; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG ELUTING SINUS STENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBASE; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; IMIDAZOLES; INTERLEUKIN-6; OBESITY; PROSPECTIVE STUDIES; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA; VALINE;

EID: 84877126686     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.196     Document Type: Article

References (36)

1. Tilg H, Wolf AM. Adiponectin: a key fat-derived molecule regulating inflammation. Expert Opin Ther Targets 2005; 9: 245-251.
2. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14: 561-566.
3. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763-771.
4. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
5. Riera-Guardia N, Rothenbacher D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab 2008; 10: 367-375.
6. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
7. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
8. Takagi H, Umemoto T. Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials. Int J Cardiol 2012; 155: 448-451.
9. Higgins JP, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In Higgins JP and Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration, 2011, Available from www.cochrane-handbook.org.
10. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769-773.
11. Ba?hr IN, Tretter P, Kru?ger J, Stark RG, Schimkus J, Unger T, Kappert K, Scholze J, Parhofer KG, Kintscher U. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-g target genes in patients with the metabolic syndrome. Hypertension 2011; 58: 725-732.
12. Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006; 29: 849-856.
13. Hong SJ, Shim WJ, Choi JI, Joo HJ, Shin SY, Park SM, Lim SY, Lim DS. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 2007; 100: 1625-1629.
14. Hong SJ, Choi SC, Ahn CM, Park JH, Kim JS, Lim DS. Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients. Heart 2011; 97: 1425-1432.
15. Huang GZ, Tang YH, Wang BY, Zhang B, Hu TJ, Zhang L, Zhang XY, Zhong Y. Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity. Saudi Med J 2011; 32: 1017-1021.
16. Link A, Lenz M, Legner D, Bo?hm M, Nickenig G. Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes. J Hypertens 2006; 24: 1891-1898.
17. Nakamura T, Inoue T, Suzuki T, Kawagoe Y, Ueda Y, Koide H, Node K. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res 2008; 31: 841-850.
18. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Yamada S, Ueda Y, Koide H. Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. Am J Med Sci 2012; 343: 46-51.
19. Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, Uchino H, Fujitani Y, Hirose T, Kawamori R. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13.
20. Nagel JM, Tietz AB, Go?ke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 2006; 55: 1149-1154.
21. Wohl P, Krusinová E, Hill M, Kratochvilova S, Zidková K, Kopecký J, Neskudla T, Pravenec M, Klementová M, Vrbikov J, Wohl P, Mlejnek P, Pelikanova T. Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. Eur J Endocrinol 2010; 163: 573-583.
22. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessì M, Madeddu C, Massa E, Mercuro G. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicininduced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 2010; 160: e1-e7.
23. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-1804.
24. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 1745-1751.
25. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-737.
26. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487-37491.
27. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
28. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Adiponectin MatsuzawaY. a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-1732.
29. Sigrist S, Bedoucha M, Boelsterli UA. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of noninsulin- dependent diabetes. Biochem Pharmacol 2000; 60: 67-75.
30. Gumieniczek A, Hopka"a H, Roliń ski J, Bojarska-Junak A. Interleukin-6 and oxidative stress in plasma of alloxan-induced diabetic rabbits after pioglitazone treatment. Immunopharmacol Immunotoxicol 2006; 28: 81-91.
31. Wu ZH, Zhao SP, Chu LX, Ye HJ. Pioglitazone reduces tumor necrosis factor-alpha serum concentration and mRNA expression of adipose tissue in hypercholesterolemic rabbits. Int J Cardiol 2010; 138: 151-156.
32. Tian Q, Miyazaki R, Ichiki T, Imayama I, Inanaga K, Ohtsubo H, Yano K, Takeda K, Sunagawa K. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptorgamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta. Hypertension 2009; 53: 798-804.
33. Takagi H, Yamamoto H, Iwata K, Goto SN, Umemoto T. Effects of telmisartan on C-reactive protein levels: A meta-analysis of randomized controlled trials. Int J Cardiol 2012; 156: 238-241.
34. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor a therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63: 522-529.
35. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 2009; 6: e1000145.
36. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5: e78.